MYD88 and neoplasm: As shown in Fig. 6c, overexpression of AGAP2-AS1 promoted the expression of MyD88 in tumor tissues (Group II vs. Group I, or Group IV vs. Group III, respectively), indicating that AGAP2-AS1 regulates tumor growth and trastuzumab resistance via targeting MyD88 in vivo.